<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-08T11:29:27+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-08T07:49:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/K9zJD83hGtvRoP7Pg4OQ8w</id>
    <link href="https://mp.weixin.qq.com/s/K9zJD83hGtvRoP7Pg4OQ8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【辉瑞PD-1招募1】未接受过卡介苗的膀胱癌中比较PF-06801591联合 BCG一项 III 期、随机、开放、3个平行组研究</title>
    <updated>2020-12-08T07:49:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/kC7WEVyXC1Y8Ot6AghdSzA</id>
    <link href="https://mp.weixin.qq.com/s/kC7WEVyXC1Y8Ot6AghdSzA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】注射用A型肉毒毒素用于治疗中、重度眉间纹的多中心、随机、双盲、阳性药平行对照的安全性和有效性临床研究</title>
    <updated>2020-12-08T07:49:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/91AuDq_2nqAAFkAPfXJa5Q</id>
    <link href="https://mp.weixin.qq.com/s/91AuDq_2nqAAFkAPfXJa5Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-07T08:56:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/KXrDf_MQub1DXGqfgEYajA</id>
    <link href="https://mp.weixin.qq.com/s/KXrDf_MQub1DXGqfgEYajA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项多中心、开放，评价西达珠单抗在晚期黑色素瘤和尿路上皮癌患者中安全性、耐受性和药代动力学的Ia/Ib期临床研究</title>
    <updated>2020-12-07T08:56:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/E8fDL3cN748lHAxGZgfixg</id>
    <link href="https://mp.weixin.qq.com/s/E8fDL3cN748lHAxGZgfixg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-06T09:23:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/Op8tAw4LBpAuU44i7zG9YQ</id>
    <link href="https://mp.weixin.qq.com/s/Op8tAw4LBpAuU44i7zG9YQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项 TALAZOPARIB 单药用于中国晚期实体瘤参加者的药代动力学、安全性和抗肿瘤活性的开放、单臂、I 期研究</title>
    <updated>2020-12-06T09:23:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/7zPao7oMA4D_OdW1qx-2Ig</id>
    <link href="https://mp.weixin.qq.com/s/7zPao7oMA4D_OdW1qx-2Ig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-05T10:08:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/QSr-ahKm1I-mcesxMjzoXg</id>
    <link href="https://mp.weixin.qq.com/s/QSr-ahKm1I-mcesxMjzoXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】氟唑帕利胶囊联合mFOLFIRINOX化疗作为胰腺癌新辅助和辅助化疗的耐受性、安全性和疗效的I期临床研究</title>
    <updated>2020-12-05T10:08:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/tPya8w3DBpwOuB5W6mzsEg</id>
    <link href="https://mp.weixin.qq.com/s/tPya8w3DBpwOuB5W6mzsEg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-04T08:55:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/cXsuNxVRwBAwhZlEpIHGlg</id>
    <link href="https://mp.weixin.qq.com/s/cXsuNxVRwBAwhZlEpIHGlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】GSK3359609联合帕博利珠单抗一线治疗PD-L1 阳性复发/转移性头颈鳞癌的随机、适应性II/III 期研究</title>
    <updated>2020-12-04T08:55:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/623-yEX0kT9qlFjfsjb3zA</id>
    <link href="https://mp.weixin.qq.com/s/623-yEX0kT9qlFjfsjb3zA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项评价BMS-986165在中度至重度斑块型银屑病患者中的长期安全性和有效性的开放标签、多中心扩展研究</title>
    <updated>2020-12-04T08:55:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/D3FS4muX29igW_5jL_zoEQ</id>
    <link href="https://mp.weixin.qq.com/s/D3FS4muX29igW_5jL_zoEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】RX518一线治疗EGFR突变的局部晚期或转移性非小细胞肺癌患者的有效性和安全性III期临床研究</title>
    <updated>2020-12-03T08:03:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/gcILjCi58XyoOWil2pqwLQ</id>
    <link href="https://mp.weixin.qq.com/s/gcILjCi58XyoOWil2pqwLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项评价CBP-201治疗中重度特应性皮炎的有效性、安全性、药代动力学和药效学的随机、双盲、安慰剂对照、多中心研究</title>
    <updated>2020-12-03T08:03:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/2yGgvzQSgNFsRjDztBU2-w</id>
    <link href="https://mp.weixin.qq.com/s/2yGgvzQSgNFsRjDztBU2-w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】胶质母细胞瘤完成同步放化疗后淋巴细胞减少的患者中评价TJ107疗效和安全性的随机、单盲、安慰剂对照Ⅱ期临床研究</title>
    <updated>2020-12-02T09:22:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/e1t3z3uyEjkTABFbKsujlg</id>
    <link href="https://mp.weixin.qq.com/s/e1t3z3uyEjkTABFbKsujlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】盐酸杰克替尼片治疗中、重度特应性皮炎患者的多中心、随机、双盲、安慰剂平行对照II期临床研究</title>
    <updated>2020-12-02T09:22:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/1yydIdSIFwRNCKCIys__Vw</id>
    <link href="https://mp.weixin.qq.com/s/1yydIdSIFwRNCKCIys__Vw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达CTLA-4招募6】评估IBI310联合信迪利单抗晚期宫颈癌的有效性和安全性的随机、双盲、对照的平行队列Ⅱ期临床研究</title>
    <updated>2020-12-01T15:25:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/k7sNTCuyGy47gyzQDurBUQ</id>
    <link href="https://mp.weixin.qq.com/s/k7sNTCuyGy47gyzQDurBUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项评估巴瑞替尼在重度或极重度斑秃成人患者中的有效性和安全性的多中心、随机、双盲、安慰剂对照、3期研究</title>
    <updated>2020-12-01T15:25:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/QkDFau_xKRtMAS5gECCPmw</id>
    <link href="https://mp.weixin.qq.com/s/QkDFau_xKRtMAS5gECCPmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【罗氏PD-L1招募患者27】阿替利珠单抗和曲妥珠单抗联合卡培他滨和奥沙利铂用于HER2阳性局部进展期可切除胃癌的II期临床研究</title>
    <updated>2020-11-30T07:53:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/I9l0X3_n7_qXhliKTc1yGg</id>
    <link href="https://mp.weixin.qq.com/s/I9l0X3_n7_qXhliKTc1yGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估Hemay808不同浓度给药方案用于轻中度特应性皮炎患者的多中心、随机、盲法、赋形剂平行对照的Ⅱ期临床研究</title>
    <updated>2020-11-30T07:53:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/LpjFI1U3AmOf4zDW6LjU1A</id>
    <link href="https://mp.weixin.qq.com/s/LpjFI1U3AmOf4zDW6LjU1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>